CEWG January 09 Full Report - National Institute on Drug Abuse

More documents

Recommendations

Info

Section IV. Across <strong>CEWG</strong> Areas: Treatment Admissions, Forensic Laboratory Analysis Data, and Average Drug Price and Purity Data PCP ranked 4th in drug items identified in 7th in Los Angeles, and 10th each in Maryland, NFLIS data in the first half of 2008 in Washington, Chicago, and Texas (section II, table 1). DC, 5th in New York City, 6th in Philadelphia, Table 13. GHB, Ketamine, LSD, and PCP Items <strong>Report</strong>ed by Forensic Laboratories in 22 <strong>CEWG</strong> Areas, by Number and Percentage of Total Items Identified 1 : 1H 2008 2 <strong>CEWG</strong> GHB Ketamine LSD PCP Total Area # (%) # (%) # (%) # (%) Items Albuquerque 0 * 0 * 0 * 0 * 733 Atlanta 0 * 32 * 5 * 0 * 6,779 Baltimore City 0 * 1 * 1 * 16 * 28,288 Boston 8 * 13 * 6 * 10 * 14,921 Chicago 7 * 25 * 27 * 82 * 40,400 Cincinnati 0 * 1 * 3 * 0 * 7,011 Denver 0 * 3 * 9 * 0 * 4,252 Detroit 0 * 1 * 0 * 0 * 3,527 Honolulu 0 * 0 * 0 * 0 * 1,143 Los Angeles 18 * 37 * 5 * 236 * 29,567 Maryland 0 * 5 * 2 * 83 * 33,219 Miami 0 * 12 * 3 * 0 * 16,015 Minneapolis/ 0 * 0 * 4 * 0 * 2,502 St. Paul New York City 4 * 92 * 4 * 394 1.5 27,064 Philadelphia 0 * 0 * 3 * 428 2.7 16,057 Phoenix 0 * 2 * 0 * 12 * 3,372 San Diego 1 * 6 * 1 * 25 * 10,234 San Francisco 21 * 26 * 4 * 11 * 11,925 Seattle 2 * 0 * 5 * 7 * 1,573 St. Louis 1 * 6 * 6 * 17 * 9,605 Texas 45 * 77 * 19 * 199 * 47,868 Washington, DC 1 * 5 * 0 * 130 5.6 2,3<strong>09</strong> 1 Only percentages of 1.0 or higher are reported in this table; percentages of less than 1.0 are indicated by the symbol *. 2 Data are for the first half of 2008: <strong>January</strong>–June 2008. SOURCE: All data were received from NFLIS, DEA, <strong>January</strong> 4, 20<strong>09</strong> (see appendix table 2); data are subject to change and may differ according to the date on which the data were queried Proceedings of the Community Epidemiology Work Group, <strong>January</strong> 20<strong>09</strong> 97
EpidEmiologic TrEnds in drug AbusE: HigHligHTs And ExEcuTivE summAry Other Drugs (BZP, TFMPP, Foxy Methoxy, Carisoprodol) BZP (1-Benzylpiperazine). In the first half of 2008, BZP emerged among the top 25 identified drugs in NFLIS forensic laboratories in 16 of 22 <strong>CEWG</strong> areas. The six exceptions were: Albuquerque, Atlanta, Cincinnati, Philadelphia, New York City, and San Diego. This contrasts with CY 2007 when none of the 22 <strong>CEWG</strong> areas, with the exception of Detroit, listed BZP-containing drug items among the top 25 drugs identified in forensic laboratories. In Detroit, 11 BZP items were identified in CY 2007, representing 0.1 percent of all drug items identified, while in the first half of 2008, 20 items, or 0.6 percent of drug items in the half-year period, were so identified. In Seattle, for example, 1.8 percent (n=29) of drug items identified in the first half of 2008 contained BZP, compared with none in CY 2007. Section II, table 1 shows BZP rankings among the top 10 most frequently identified drug items in NFLIS data in the first half of 2008. BZP ranked 7th in Seattle and Chicago, 9th in Washington, DC and Miami/ Dade County, and 10th in Honolulu and Detroit. TFMPP or 1-(3-Trifluoromethylphenyl) Piperazine. The identification of this drug in top 25 NFLIS data for the first half of 2008 was localized to two areas—Atlanta and Washington, DC. Atlanta reported an increase in items containing TFMPP in the first half of 2008, compared with CY 2007, reporting 16 such drug items in CY 2007 and 117 in the first half of 2008. This represents an increase from 0.1 percent to 1.7 percent of drug items identified in the respective periods. In the first half of 2008 forensic laboratory data, TFMPP ranked seventh in Washington, DC and eighth in frequency among drug items identified in Atlanta (section II, table 1). Foxy or Foxy Methoxy (5-Methoxy-N,N- Diisopropyltryptamine, or 5-MeO-DIPT). No Foxy Methoxy drug items were identified in any <strong>CEWG</strong> areas among the top 25 in CY 2007, with the exception of Seattle (n=5). In the first half of 2008, however, Denver (n=91) and Phoenix (n=3) both reported identification of this drug. Increasing from none in CY 2007, 19 drug items were identified in Denver in the first half of 2008, 18 of which this drug represented 0.5 percent of total drug items in that area. Eighteen of the 19 such drug items identified were identified in Arapahoe County, a suburban county south of Denver in the Denver MSA. This drug ranked 10th among the most frequently identified drug items in Denver in this reporting period (section II, table 1). Carisoprodol. Drug items containing carisoprodol ranked eighth in Texas and tenth in Atlanta, Los Angeles, and Phoenix among the most frequently identified items in the first half of 2008 for 22 <strong>CEWG</strong> areas (section II, table 1). <strong>Report</strong>ed among the top 25 most commonly identified drugs in both CY 2007 and the first half of 2008, carisoprodol items increased slightly over the two periods in Atlanta and Los Angeles. In Atlanta, carisoprodol-containing drug items represented 0.7 percent (n=103) of drug items identified in CY 2007 and 0.9 percent (n=60) in the first half of 2008, while they represented 0.2 percent (n=123) and 0.3 percent (n=86) in the respective periods in Los Angeles. Percentages were stable over the two reporting periods for Phoenix, San Diego, and Texas. 98 Proceedings of the Community Epidemiology Work Group, <strong>January</strong> 20<strong>09</strong>
Page 1 and 2:
EpidEmiologic TrEnds in drug AbusE
Page 3 and 4:
EpidEmiologic TrEnds in drug AbusE:
Page 5 and 6:
Page 7 and 8:
Foreword Foreword This Executive Su
Page 9 and 10:
Page 11 and 12:
Page 13 and 14:
Page 15 and 16:
Page 17 and 18:
Page 19 and 20:
Page 21 and 22:
Page 23 and 24:
Page 25 and 26:
Page 27 and 28:
Page 29 and 30:
Page 31 and 32:
Page 33 and 34:
Page 35 and 36:
58.9 17.5 1.8 1.5 EpidEmiologic TrE
Page 37 and 38:
Page 39 and 40:
Page 41 and 42:
Page 43 and 44:
Page 45 and 46:
Page 47 and 48:
Page 49 and 50:
Page 51 and 52:
Page 53 and 54: EpidEmiologic TrEnds in drug AbusE:
Page 103: EpidEmiologic TrEnds in drug AbusE:
Page 115 and 116: Participant List Participant List <
Page 117 and 118: Participant List Daniel P. Dooley S
Page 119 and 120: Participant List John A. Newmeyer,
Page 121: NIH Publication No. 09</str
show all

CEWG January 09 Full Report - National Institute on Drug Abuse

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?